EMA Refused: EnCyzix (enclomifene citrate) — Renable Pharma Limited

View source ↗

Summary

The EMA refused marketing authorization for EnCyzix (enclomifene citrate) by Renable Pharma Limited for the therapeutic area of hypogonadism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism

Drugs mentioned

• EnCyzix (enclomifene citrate)

Snippet

Status: Refused. Therapeutic area: Hypogonadism. MAH: Renable Pharma Limited. Decision date: 26/01/2018